ArticleAbdominal radiology (New York)2026
Integrated dual-energy CT spectral kinetics and subregional habitat phenotyping for preoperative prediction of perineural invasion in gastric adenocarcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerineural invasion (PNI) is a key prognostic determinant in gastric adenocarcinoma but remains radiologically occult on conventional CT. PURPOSE: To develop and validate an integrated model combining dual-energy CT (DECT)-derived functional spectral slopes and subregional habitat signatures for the preoperative prediction of PNI. MATERIALS AND
methodsIn this retrospective study, 175 patients (median age, 66 years; interquartile range, 58-73 years; 131 men) with gastric adenocarcinoma who underwent preoperative DECT between 2023 and 2025 were evaluated. Patients were randomized into a training cohort (n = 122) and an internal test cohort (n = 53). Tumor subregions were parcellated into three biologically distinct habitats using voxel-wise clustering. Stable habitat features (ICC ≥ 0.75), three-phase spectral slopes, and a Habitat-Graph Neural Network (H-GNN)-derived Topological Interaction Score (TIS)-capturing spatial adjacency relationships between habitat subregions-were collectively submitted as candidate predictors to LASSO regression for construction of the final Spectral-Habitat Signature. Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC). Clinical utility was assessed via decision curve analysis.
resultsPNI was pathologically confirmed in 46.9% (82 of 175) of patients. The integrated Spectral-Habitat model achieved an AUC of 0.832 (95% CI: 0.760, 0.898) in the training cohort and 0.758 (95% CI: 0.666, 0.845) in the internal test cohort. A stratified 5-fold cross-validation demonstrated the stability of the framework, yielding a mean AUC of 0.765 (SD, 0.084). The combined model significantly outperformed the extracellular volume (ECV) model (AUC, 0.758 vs. 0.544; P < .001). Equilibrium-phase spectral slope emerged as a decisive functional biomarker. Model calibration was excellent in the test cohort (P = .560, Hosmer-Lemeshow test). Decision curve analysis demonstrated a substantial net clinical benefit across threshold probabilities of 10%-80%.
conclusionIn this retrospective single-center study, an integrated model leveraging functional spectral kinetics and subregional spatial heterogeneity showed potential for the preoperative stratification of occult perineural invasion. However, these preliminary findings derived from a limited sample size require further validation in larger, multi-institutional prospective cohorts before clinical implementation in surgical planning.
Indexed as
Identifiers
42440112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.